Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

NCT03891355 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Carfilzomib
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Fondazione Italiana Linfomi - ETS